Spyre rises after bowel disease drug succeeds mid-stage study

Spyre Therapeutics

13/04/2026 12:49

** Shares of drug developer Spyre Therapeutics  SYRE.O rise 23.3% to $63.24 premarket

** SYRE says its experimental drug showed a significant reduction in disease activity in a mid-stage study in patients with ulcerative colitis

**  The drug, SPY001, met the main goal of the trial, reducing a key measure of tissue-level inflammation after 12 weeks of treatment, co says

**  Ulcerative colitis is a chronic inflammatory disease causing swelling and ulcers in the lining of the colon and rectum

** As of last close, SYRE stock was up 56% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))